Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results

Parkinsonism and Related Disorders

Volumn 19, Issue 3, 2013, Pages 339-345

  Fernandez, Hubert H ^a   Vanagunas, Arvydas ^b   Odin, Per ^c,d   Espay, Alberto J ^e   Hauser, Robert A ^f   Standaert, David G ^g   Chatamra, Krai ^h   Benesh, Janet ^h   Pritchett, Yili ^h   Hass, Steven L ^h   Lenz, Robert A ^h  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Klinikum Bremerhaven Reinkenheide   (Germany)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h ABBOTT LABORATORIES   (United States)

Author keywords

Levodopa carbidopa intestinal gel; Motor fluctuations; Parkinson's disease; PEG J procedure; Pump administration

Indexed keywords

CARBIDOPA PLUS LEVODOPA; HYDROXOCOBALAMIN;

ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; ARTICLE; BACKACHE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAINTNESS; FEMALE; GASTROINTESTINAL DISEASE; GASTROJEJUNOSTOMY; GEL; HIP FRACTURE; HUMAN; INFUSION PUMP; INSOMNIA; INTESTINE OBSTRUCTION; INTESTINE ULCER; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPEN STUDY; OROPHARYNX PAIN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERCUTANEOUS ENDOSCOPIC GASTROJEJUNOSTOMY; PERITONITIS; PNEUMONIA; PNEUMOPERITONEUM; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIUS FRACTURE; RETROPERITONEAL ABSCESS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; INFUSION PUMPS; JEJUNUM; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84874284001     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.11.020     Document Type: Article

References (34)

1. Yahr M.D., Duvoisin R.C., Schear M.J., Barrett R.E., Hoehn M.M. Treatment of parkinsonism with levodopa. Arch Neurol 1969, 21:343-354.
2. Hauser R.A. Levodopa: past, present, and future. Eur Neurol 2009, 62:1-8.
3. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonuccelli U., Damier P., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004, 19:997-1005.
4. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004, 62:S47-S55.
5. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5:677-687.
6. Pechevis M., Clarke C.E., Vieregge P., Khoshnood B., Deschaseaux-Voinet C., Berdeaux G., et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 2005, 12:956-963.
7. Politis M, Wu K, Molloy S, P GB, Chaudhuri KR, Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord 25:1646-51.
8. Hauser R.A., Friedlander J., Zesiewicz T.A., Adler C.H., Seeberger L.C., O'Brien C.F., et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000, 23:75-81.
9. Chapuis S., Ouchchane L., Metz O., Gerbaud L., Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005, 20:224-230.
10. Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009, 15:S9-S15.
11. Chase T.N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998, 55:1-9.
12. Kurlan R., Rothfield K.P., Woodward W.R., Nutt J.G., Miller C., Lichter D., et al. Erratic gastric emptying of levodopa may cause " random" fluctuations of parkinsonian mobility. Neurology 1988, 38:419-421.
13. Nutt J.G., Woodward W.R., Hammerstad J.P., Carter J.H., Anderson J.L. The " on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984, 310:483-488.
14. Antonini A., Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother 2009, 9:859-867.
15. Lundqvist C. Continuous levodopa for advanced Parkinson's disease. Neuropsychiatr Dis Treat 2007, 3:335-348.
16. Antonini A., Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2009, 15:S97-S100.
17. Stocchi F., Vacca L., Ruggieri S., Olanow C.W. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005, 62:905-910.
18. Nyholm D., Nilsson Remahl A.I., Dizdar N., Constantinescu R., Holmberg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005, 64:216-223.
19. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009, 24:993-1000.
20. Fernandez H.H., Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Curr Med Res Opin 2011, 27:907-919.
21. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006, 6:1403-1411.
22. Nyholm D., Askmark H., Gomes-Trolin C., Knutson T., Lennernas H., Nystrom C., et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003, 26:156-163.
23. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005, 62:241-248.
24. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
25. Rinne U.K., Larsen J.P., Siden A., Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998, 51:1309-1314.
26. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006, 355:896-908.
27. Weaver F.M., Follett K., Stern M., Hur K., Harris C., Marks W.J., et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. J Am Med Assoc 2009, 301:63-73.
28. Fang J.C. Minimizing endoscopic complications in enteral access. Gastrointest Endosc Clin N Am 2007, 17:179-196.
29. McClave S.A., Chang W.K. Complications of enteral access. Gastrointest Endosc 2003, 58:739-751.
30. Schrag A., Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000, 123:2297-2305.
31. Toth C., Breithaupt K., Ge S., Duan Y., Terris J.M., Thiessen A., et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010, 68:28-36.
32. Toth C., Brown M.S., Furtado S., Suchowersky O., Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008, 23:1850-1859.
33. Müller T. Role of homocysteine in the treatment of Parkinson's disease. Expert Rev Neurother 2008, 8:957-967.
34. Müller T., Kuhn W. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Mov Disord 2009, 24:1339-1343.